• Medicure outlined a US-focused strategy built around expanding ZYPITAMAG, AGGRASTAT, Marley Drug pharmacy operations, targeted R&D, acquisitions.
• 2025 net revenue: ZYPITAMAG CAD 6.5 million, up 5%; Marley Drug CAD 20.3 million, up 88%; AGGRASTAT CAD 5.7 million, up 29%.
• Marley Drug positioned as a direct-to-consumer channel for ZYPITAMAG, aiming to reduce wholesaler and pharmacy benefit manager fees.
• Phase 3 MC-1 trial for PNPO deficiency targets 10-15 patients; approval could yield a priority review voucher, with prior sales near USD 200 million.
• Balance sheet framed as debt-free; 2025 cash use included CAD 2.04 million for Gateway Medical Pharmacy, West Olympia Pharmacy acquisitions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicure Inc. published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.